Abstract: Various aspects of the present disclosure are directed toward apparatuses, systems, and methods that include a single pass implantable lead configured to be coupled to the implantable medical device and arranged on a left ventricle and left atrium of a patient. The lead may include a proximal region having at least one electrode, a distal region having at least one electrode, and an intermediate region therebetween. The system can sense and pace the left atrium and the left ventricle.

Abstract: A method treating cancer in a subject comprises administering to the subject a therapeutically effective amount of an antimetabolite agent that induces formation of AP sites in cancer cells of the subjects and an amount AP endonuclease inhibitor effective to potentiate the cytotoxicity of the antimetabolite agent to the cancer cells.

Abstract: A temporary neurostimulation lead may be secured relative to patient using a fixation device. The fixation device may include an attachment portion that is configured to be releasably fixated to the patient and a lead fixation portion that is configured to secure the temporary neurostimulation lead. The fixation device can be adhesively fixated to the patient via the attachment portion and the temporary neurostimulation lead can be fixated to the lead fixation portion of the fixation device.

Abstract: A method of cleaning or conditioning a paper-making press felt or other substrate is described. The method includes treating the paper-making press felt or other substrate with a formulation that contains at least solketal.

Abstract: Medical devices and methods for making and using medical devices are disclosed. An example medical device may include an implantable medical device. The implantable medical device may include an implantable pacing member having a housing and a lead input. A lead may be coupled to the lead input. The lead may be designed to extend along a pericardial space, epicardium, or both and engage a heart chamber. A passageway may be defined along a portion of the length of the lead.

Abstract: The disclosure relates to a needle assembly for delivering a lead and methods of use. The needle assembly is configured to cut tissue and reduce the potential for cutting vulnerable bodily structures. The needle assembly includes an outer needle with a blunt tip and an inner needle with a sharp tip. The outer needle may be curved, and the inner needle may be curved. When the inner needle is rotated with respect to the outer needle, the inner needle protracts or retracts with respect to the outer needle. A stopping feature on the needle assembly may be included to resist over-rotation or over-extension. The needle assembly provides an initial path that may be further dilated for delivering a lead, such as a vagus nerve stimulation lead to a target site. The target site may be electrically tested with some embodiments.

Abstract: A method for estimating a traffic rate between a virtual machine pair, and a related device are provided. When a rate of traffic sent by a virtual machine vm-x1 to a virtual machine vm-y1 is estimated, reference is made to at least rates of sending traffic by N21 virtual machines deployed in N2 physical hosts and including the virtual machine vm-x1, rates of traffic sent by N1 switching devices to N4 switching devices, rates of receiving traffic of N31 virtual machines deployed in N3 physical hosts and including the virtual machine vm-y1, and rates of outgoing traffic of the N4 switching devices, thereby facilitating relatively accurate estimation of a traffic rate between a virtual machine pair.

Abstract: Various aspects describe a lead delivery system for percutaneous introduction of a lead to a stimulation site near a neural target, such as the vagus nerve for nerve stimulation. The lead delivery system may include a needle assembly having a needle adapted to cut through tissue and provide initial access into the carotid sheath. The needle may be retracted into the lead delivery system to prevent cutting structures in the carotid sheath. The lead delivery system may also include a dilator assembly having one or more dilators to dilate a path to the stimulation site. The lead delivery system may further comprise a dilator assembly including a retractable needle adapted to cut through tissue. One or more locating elements, alternatively or in addition to one or more imaging elements, may be used on individual components of the lead delivery system for enhanced trackability and locatability within the body.

Abstract: The present application provides a an image compensation method for side-emitting backlight comprising steps of: S1, dividing the display screen into several regions; S2, arranging virtual light sources at one side of each region where actual light sources are located for imitating the actual light sources; S3, inputting a pixel value and a coordinate of the point to be compensated; S4, computing a ratio value between an all-full-lighting backlight brightness of the point to be compensated when fully lighted and an all-reduced backlight brightness of the point to be compensated when reduced in brightness; S5, obtaining a compensation factor of the point to be compensated, according to the ratio value; S6, compensating the pixel value of the point to be compensated by using the compensation factor; S7, determining whether all the points to be compensated in the image to be compensated have been compensated or not.

Abstract: The present invention belongs to the electrochemical field. Specifically, the present invention relates to a charge and discharge lithium battery having high energy density. The lithium battery consists of a separator, a cathode, an anode and an electrolyte, wherein the separator is a solid and allows lithium ions to reversibly pass through; the cathode is made of metal lithium or an alloy of lithium; the electrolyte at the cathode side is a common organic electrolyte, a polymer electrolyte, or an ionic liquid electrolyte, or a mixture thereof; the anode is an anode material commonly used in a lithium ion battery; the electrolyte at the anode side is an aqueous solution or a hydrogel electrolyte containing lithium salt. The energy density of the charge and discharge lithium battery is higher than the energy density of the traditional lithium ion battery by at least 30%. The charge and discharge lithium battery having high energy density can be used for storage and discharge of electric power.

Abstract: Methods, systems, and computer program products are provided for measuring effectiveness of content items included in a campaign. One example method includes providing a corpus of campaigns, where a campaign defines parameters for presentation that specify circumstances under which content items are presented to users in response to requests. The corpus is filtered by identifying one or more candidate campaigns, where each of the identified candidate campaigns is associated with a geographic region and includes one or more constraints that permit pausing distribution of content items without compromising campaign goals. For each candidate campaign, one or more experimental geographic locations included in the geographic region are determined that are substantially representative of the region. Presentation of at least one of the content items is paused for a time period, and content item effectiveness is measured by comparing resource conversions for experimental and control geographic locations.

Abstract: In one embodiment, a method of performing a merge operation can include: mapping a business process modeling notation (BPMN) model to a business process execution language (BPEL) model; modifying the BPMN model to form a modified BPMN model; modifying the BPEL model to form a modified BPEL model; when the merge operation is a forward merge operation: exporting the modified BPMN model to an exported BPEL model; performing an activity level outline merge for added information technology (IT) scopes and branches from the modified BPEL model; performing an activity level detail merge for added IT details from the modified BPEL model; and performing an attribute level merge for updated branch conditions in the merged BPEL model; and when the merge operation is a reverse merge operation, adding scopes and branches from the modified BPEL model to the BPMN model.

Abstract: An inspiratory muscle stimulation system uses an implantable medical device to deliver stimulation to control diaphragmatic contractions for slower and deeper breathing, thereby conditioning and strengthening inspiratory muscles. In various embodiments, respiratory and/or cardiac performance are monitored for controlling parameters of the stimulation.

Abstract: Electrode displacement can be detected using a thoracic impedance or conductivity signal. The thoracic impedance or conductivity signal can be filtered to attenuate cardiac contraction (stroke) and respiration components. A fluid status component of the thoracic impedance or conductivity signal can be used to detect a posture-shift related electrode displacement, such as can result from left ventricular/coronary sinus (LV/CS) lead pullback upon a recumbent to upright posture shift.

Abstract: Described is a system for stimulating a target region of a vagus nerve from a location within an internal jugular vein. The system comprises a medical lead and an insulating element. The insulating element is formed from a flexible sheet of electrically insulative material, and is to be implanted within the internal jugular vein to insulate nerve structures proximate the vagus nerve from stimulation. The insulating sheath includes at least one window through which the electrical stimuli can be delivered to the target region of the vagus nerve.

Abstract: A method of treating a neoplastic disease in a subject includes administering to neoplastic cells of the subject an MGMT inhibitor and at least one of an antimitotic agent or a DNA damaging agent.

Abstract: Devices or methods such as for stimulating excitable tissue or sensing physiologic response or other signals that can use separate fixation mechanism is described. An implantable apparatus can include a modular electrostimulation electrode assembly that can include a first module and a second module that can be end user-attachable to each other and end user-detached from each other. The first module can include an electrostimulation electrode fixation support member that can be laid flat against or otherwise conform to a surface of a heart, and can define a centrally located open portal such as for permitting electrode access to the surface of the heart. The second module can include an electrostimulation electrode that can be inserted through the portal of the fixation support member such as to contact the surface of the heart such as to deliver chronic electrostimulation to the heart.

Abstract: A system and method for detecting and treating symptoms of early decompensation utilizing a cardiac rhythm management. The system applies an electrical stimulus to the patient's heart at a first set of pacing parameters including a lower rate limit (LRL) setting, and acquires a coronary venous pressure (CVP) signal from a pressure sensor implanted in a coronary vein of the patient. An average coronary venous end diastolic pressure (CV-EDP) value is calculated from the CVP signal. The system monitors the average CV-EDP value over a predetermined interval, and dynamically adjusts the LRL setting responsive to the detection of a first or a second predetermined event based on the average CV-EDP value.

Abstract: A system and method for estimating a hemodynamic performance parameter value of a patient's heart. The system includes a pulse generator and a medical electrical lead implanted partially within a coronary vein of the heart. The lead includes at least one sensor located within the coronary vein configured to generate a signal indicative of at least one dimensional parameter of the coronary vein. Changes in the dimensional parameter during one or more cardiac cycles are measured. The hemodynamic performance parameter is estimated based on the change in the dimensional parameter of the coronary vein.

Abstract: A method of treating a neoplastic disease in a subject includes administering to neoplastic cells of the subject an MGMT inhibitor and at least one of an antimitotic agent or a DNA damaging agent.